6 days Ago By ABMN Staff
XTX Topco Ltd lessened its stake in shares of Cardiff Oncology, Inc. ( NASDAQ:CRDF – Free Report ) by 66.1% during the fourth quarter, Holdings Channel.
com reports. The fund owned 40,763 shares of the company’s stock after selling 79,621 shares during the period. XTX Topco Ltd’s holdings in Cardiff Oncology were worth $177,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in CRDF. State Street Corp boosted its holdings in shares of Cardiff Oncology by 3.4% in the 3rd quarter.
State Street Corp now owns 832,652 shares of the company’s stock valued at $2,223,000 after purchasing an additional 27,628 shares in the last quarter. Barclays PLC boosted its holdings in shares of Cardiff Oncology by 291.9% in the 3rd quarter.
Barclays PLC now owns 53,089 shares of the company’s stock valued at $141,000 after purchasing an additional 39,542 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cardiff Oncology by 1.9% in the 3rd quarter.
Geode Capital Management LLC now owns 928,232 shares of the company’s stock valued at $2,479,000 after purchasing an additional 17,557 shares in the last quarter. HB Wealth Management LLC acquired a new stake in shares of Cardiff Oncology in the 4th quarter valued at $105,000. Finally, Rhumbline Advisers boosted its holdings in shares of Cardiff Oncology by 24.
0% in the 4th quarter. Rhumbline Advisers now owns 53,172 shares of the company’s stock valued at $231,000 after purchasing an additional 10,290 shares in the last quarter. Institutional investors own 16.
29% of the company’s stock. Wall Street Analyst Weigh In Separately, HC Wainwright raised their target price on Cardiff Oncology from $13.00 to $17.
00 and gave the company a “buy” rating in a report on Friday, February 28th. Cardiff Oncology Stock Up 2.4 % NASDAQ CRDF opened at $2.
95 on Tuesday. The company has a market cap of $196.25 million, a price-to-earnings ratio of -3.
14 and a beta of 1.74. Cardiff Oncology, Inc.
has a twelve month low of $2.01 and a twelve month high of $5.64.
The business’s fifty day moving average is $3.43 and its 200 day moving average is $3.48.
Cardiff Oncology Profile ( Free Report ) Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. Recommended Stories Want to see what other hedge funds are holding CRDF? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Cardiff Oncology, Inc. ( NASDAQ:CRDF – Free Report ). Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.
com's FREE daily email newsletter ..
